{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:47:57Z","timestamp":1792597677430,"version":"4.5.0"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Initial enfortumab vedotin (EV) dose selection is increasingly relevant in advanced urothelial carcinoma (UC). Reduced starting doses may be selected for some patients, but their associations with clinical outcomes and tolerability remain uncertain.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the association of physician-selected initial EV dose reduction with clinical outcomes among patients with advanced UC.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective multicenter cohort study of patients with advanced UC who initiated EV monotherapy after platinum-based chemotherapy and immune checkpoint inhibition was conducted at 18 institutions in Korea from January 1, 2023, to May 31, 2025, with follow-up through May 31, 2026. Data were analyzed in June 2026.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Initial EV dose reduction at first administration, before treatment-related toxicity. The primary comparison was reduced-dose (\u226510% reduction) vs full-dose (&amp;lt;10% reduction) EV monotherapy; post hoc analyses used less than 10%, 10% to 20%, and greater than 20% categories.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Progression-free survival (PFS) and overall survival (OS) were the primary outcomes. Secondary outcomes included objective response and treatment-emergent peripheral neuropathy (PN).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 368 patients (median [IQR] age, 68.0 [62.0-74.0] years; 267 male [72.6%] and 101 female [27.4%]), median (IQR) follow-up was 15.4 (8.4-20.0) months. Median PFS was 5.7 months in the reduced-dose group and 6.3 months in the full-dose group (adjusted hazard ratio [HR], 1.24; 95% CI, 0.95-1.61); median OS was 10.1 and 10.5 months, respectively (adjusted HR, 1.07; 95% CI, 0.81-1.43). Objective response occurred in 65 of 146 response-evaluable patients (44.5%) in the reduced-dose group and 95 of 179 (53.1%) in the full-dose group. Grade 3 or higher PN occurred in 6 of 170 reduced-dose patients (3.5%) and 20 of 198 full-dose patients (10.1%) (adjusted odds ratio, 0.26; 95% CI, 0.09-0.73). In post hoc analyses, reductions exceeding 20% were associated with shorter PFS compared with the full-dose group (adjusted HR, 1.40; 95% CI, 1.01-1.95), although the overall 3-group comparison was not statistically significant.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this multicenter cohort study, physician-selected initial EV dose reduction was not significantly associated with survival or response outcomes. These findings do not establish equivalence or warrant routine initial dose reduction. The lower incidence of severe PN and the exploratory PFS signal with reductions exceeding 20% are hypothesis-generating and require prospective validation.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.39846","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:00:37Z","timestamp":1792594837000},"page":"e2639846","source":"Crossref","is-referenced-by-count":0,"title":["Initial Enfortumab Vedotin Dose Reduction and Outcomes in Pretreated Advanced Urothelial Carcinoma"],"prefix":"10.1001","volume":"9","author":[{"given":"In-Ho","family":"Kim","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Seoul St Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Gon","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jungmin","family":"Jo","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Ewha Womans University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Hee","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo-Hwan","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Gil Medical Center, College of Medicine, Gachon University, Incheon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Kyun","family":"Bae","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Chonnam National University Medical School and Hwasun Hospital, Hwasun, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Jae","family":"Huh","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Ji","family":"Choi","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon-Su","family":"Im","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Jin","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoungmin","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Oncology\/Hematology, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Young","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hyun","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Hemato-oncology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Jun","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Medical Oncology, Department of Internal Medicine, Chung-Ang University Hospital, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haa-Na","family":"Song","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongsik","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong-Hoon","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kosin University Gospel Hospital, Busan, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inkeun","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"issue":"17","key":"zoi261078r1","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi261078r2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","article-title":"Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986.","volume":"30","author":"De Santis","year":"2012","journal-title":"J Clin Oncol"},{"issue":"11","key":"zoi261078r3","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma.","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"issue":"13","key":"zoi261078r4","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma.","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"issue":"19","key":"zoi261078r5","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma.","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi261078r6","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma.","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi261078r7","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer.","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi261078r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2026.102501","article-title":"Real-world outcomes of patients with baseline neuropathy and\/or diabetes mellitus receiving enfortumab vedotin-based regimens for advanced urothelial carcinoma in the UNITE Database.","volume":"24","author":"Jang","year":"2026","journal-title":"Clin Genitourin Cancer"},{"key":"zoi261078r9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.801199","article-title":"Cutaneous toxicity associated with enfortumab vedotin: a real-world study leveraging U.S. Food and Drug Administration adverse event reporting system.","volume":"11","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"key":"zoi261078r10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1326715","article-title":"Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer.","volume":"14","author":"Brower","year":"2024","journal-title":"Front Oncol"},{"issue":"29","key":"zoi261078r12","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy.","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"issue":"10","key":"zoi261078r13","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1200\/JCO.19.02044","article-title":"EV-101: a phase I study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma.","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi261078r14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2025.102326","article-title":"Impact of initial relative dose intensity on tumor response and survival outcomes in enfortumab vedotin monotherapy for previously treated advanced urothelial carcinoma: a real-world analysis from a multicenter study.","volume":"23","author":"Miyake","year":"2025","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"zoi261078r15","doi-asserted-by":"publisher","first-page":"177.e1","DOI":"10.1016\/j.urolonc.2024.03.001","article-title":"Real-world use, dose intensity, and adherence to enfortumab vedotin in locally advanced or metastatic urothelial cancer.","volume":"42","author":"Mamtani","year":"2024","journal-title":"Urol Oncol"},{"issue":"7","key":"zoi261078r16","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1093\/jjco\/hyaf049","article-title":"Clinical significance of the dose modification of enfortumab vedotin monotherapy for advanced urothelial carcinoma.","volume":"55","author":"Minato","year":"2025","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"zoi261078r17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.21873\/invivo.13843","article-title":"Impact of relative dose intensity of enfortumab vedotin for advanced urothelial carcinoma.","volume":"39","author":"Furubayashi","year":"2025","journal-title":"In Vivo"},{"issue":"6","key":"zoi261078r18","doi-asserted-by":"publisher","DOI":"10.1111\/iju.70523","article-title":"Impact of early relative dose intensity on survival in patients receiving enfortumab vedotin for metastatic urothelial carcinoma: a Japanese real-world multicenter study.","volume":"33","author":"Endo","year":"2026","journal-title":"Int J Urol"},{"issue":"1","key":"zoi261078r19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1001\/jamaoncol.2025.4566","article-title":"Reduced-dose enfortumab vedotin, treatment continuity, and survival in urothelial cancer.","volume":"12","author":"Chow","year":"2026","journal-title":"JAMA Oncol"},{"issue":"3","key":"zoi261078r20","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.1200\/JOP.2017.025411","article-title":"Dose rounding of biologic and cytotoxic anticancer agents: a position statement of the hematology\/oncology pharmacy association.","volume":"14","author":"Fahrenbruch","year":"2018","journal-title":"J Oncol Pract"},{"issue":"2","key":"zoi261078r21","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"3","key":"zoi261078r22","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability.","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"19","key":"zoi261078r23","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71284","article-title":"Treatment-related adverse events and associated outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: analysis of the UNITE Study.","volume":"14","author":"Nizam","year":"2025","journal-title":"Cancer Med"},{"key":"zoi261078r24","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2021.115534","article-title":"Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): mechanistic insights into MMAE ADC peripheral neuropathy.","volume":"421","author":"Best","year":"2021","journal-title":"Toxicol Appl Pharmacol"},{"issue":"10","key":"zoi261078r25","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107778","article-title":"Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates.","volume":"26","author":"Fu","year":"2023","journal-title":"iScience"},{"issue":"1","key":"zoi261078r26","doi-asserted-by":"publisher","DOI":"10.1111\/iju.70329","article-title":"Clinical features and risk factors of enfortumab vedotin-induced peripheral neuropathy in patients with metastatic urothelial carcinoma: a multicenter retrospective study (YUSHIMA Study).","volume":"33","author":"Soma","year":"2026","journal-title":"Int J Urol"},{"issue":"5","key":"zoi261078r27","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1007\/s10147-024-02481-8","article-title":"Peripheral neuropathy and nerve electrophysiological changes with enfortumab vedotin in patients with advanced urothelial carcinoma: a prospective multicenter cohort study.","volume":"29","author":"Taoka","year":"2024","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"zoi261078r28","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ana.24951","article-title":"Chemotherapy-induced peripheral neuropathy: a current review.","volume":"81","author":"Staff","year":"2017","journal-title":"Ann Neurol"},{"issue":"1","key":"zoi261078r29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.critrevonc.2011.04.012","article-title":"Chemotherapy-induced peripheral neurotoxicity (CIPN): an update.","volume":"82","author":"Argyriou","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"issue":"15","key":"zoi261078r30","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1158\/1078-0432.CCR-18-0656","article-title":"Paclitaxel plasma concentration after the first infusion predicts treatment-limiting peripheral neuropathy.","volume":"24","author":"Hertz","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"5","key":"zoi261078r31","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1002\/cpt.3383","article-title":"Population pharmacokinetic modeling and exposure-response analysis for the antibody-drug conjugate enfortumab vedotin in locally advanced or metastatic urothelial carcinoma.","volume":"116","author":"Zuo","year":"2024","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"zoi261078r32","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1093\/oncolo\/oyac001","article-title":"Management of dermatologic events associated with the nectin-4-directed antibody-drug conjugate enfortumab vedotin.","volume":"27","author":"Lacouture","year":"2022","journal-title":"Oncologist"},{"issue":"1","key":"zoi261078r33","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102278","article-title":"Real-world evidence for enfortumab vedotin in patients with metastatic urothelial cancer: an Austrian multicentre study.","volume":"23","author":"Niedersuess-Beke","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"zoi261078r34","doi-asserted-by":"publisher","DOI":"10.1177\/17562872251412927","article-title":"Real-world use of enfortumab vedotin in metastatic urothelial carcinoma: efficacy, safety, and risk stratification.","author":"Catalano","year":"2026","journal-title":"Ther Adv Urol"},{"key":"zoi261078r35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.euros.2023.04.018","article-title":"Enfortumab vedotin in metastatic urothelial carcinoma: survival and safety in a European multicenter real-world patient cohort.","volume":"53","author":"Zsch\u00e4bitz","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"zoi261078r36","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.euros.2025.10.010","article-title":"Efficacy of enfortumab vedotin after platinum chemotherapy and pembrolizumab in metastatic urothelial carcinoma: a multicenter real-world analysis of the ARON-2EV cohort.","volume":"82","author":"Fiala","year":"2025","journal-title":"Eur Urol Open Sci"},{"issue":"4","key":"zoi261078r37","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2026.102525","article-title":"Assessing treatment outcomes of patients undergoing enfortumab vedotin dose reduction in metastatic bladder cancer.","volume":"24","author":"Rives","year":"2026","journal-title":"Clin Genitourin Cancer"},{"key":"zoi261078r11","unstructured":"Padcev (enfortumab vedotin-ejfv). Prescribing information. Astellas Pharma US, Inc; Seagen Inc. Revised February 2025. Accessed October 6, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761137s029lbl.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2855572\/kim_2026_oi_261078_1791995789.5833.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:00:38Z","timestamp":1792594838000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2855572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.39846","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]}}}